The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.

摘要: Chronic kidney disease (CKD) anemia treatment was revolutionized in the late 1980s with introduction of recombinant human erythropoietin. This and related erythropoiesis-stimulating agents (ESAs) greatly benefited patients by decreasing debilitating symptoms, improving their quality life, freeing them from dependence on blood transfusions associated complications such as infections, sensitization impeding transplantation, secondary iron overload. However, even initial studies, untoward effects were noted receiving ESAs, including worsening hypertension, seizures, dialysis access clotting. Later, increased mortality, malignancy progression stroke reported renal patients. review focuses safety issues ESAs CKD